Rhinitis, Allergic, Perennial Clinical Trial
Official title:
A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
Previous publications have indicated that Allergic Rhinitis (AR) patients suffering from both ocular and nasal symptoms have a greater burden of illness and lower quality of life than patients suffering from nasal symptoms alone. Fluticasone furoate (FF) acts against both nasal and ocular symptoms. The purpose of this study was to evaluate the differences in symptom control (both perceptually and objectively) and resource use for patients with current seasonal AR.
- Allergic rhinitis (AR) is a common inflammatory condition of the upper respiratory
tract, nasal cavity and eyes affecting up to 20% of the population in the United States
and Europe. The bothersome nature of AR symptoms can severely affect daily activities
including ability to work and examination performance and impact on quality of life
(QoL) and psychosocial well being.
- This study assesses the impact of Fluticasone furoate (FF) on the QoL of seasonal
allergic rhinitis (SAR) patients, including the number of symptom-free days (SFD) and
quality of life over the last 4 weeks, and compares this with other inhaled nasal
steroids (INS): mometasone furate (MF) and fluticasone proprionate (FP).
- Selected physicians provide information including a range of demographic, symptom and
treatment details for a number of their SAR patients. The patient themselves are then
invited to provide details about their SAR including symptoms, the impact of AR upon
their lifestyles, attitudes to treatment and completion of Health Related Quality of
Life (HRQoL) instruments.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02443805 -
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
|
Phase 3 | |
| Completed |
NCT01231464 -
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT00224523 -
Long Term Safety Of GW685698X Via Nasal Biopsy
|
Phase 3 | |
| Completed |
NCT00232518 -
Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis
|
N/A | |
| Completed |
NCT00658918 -
To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)
|
Phase 3 | |
| Completed |
NCT00404586 -
Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber
|
Phase 1 | |
| Withdrawn |
NCT02988778 -
Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT00988247 -
Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT01678807 -
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
|
Phase 1 | |
| Completed |
NCT01644617 -
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
|
Phase 2 | |
| Completed |
NCT01216384 -
Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers
|
Phase 1 | |
| Completed |
NCT00848965 -
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber
|
Phase 4 | |
| Completed |
NCT00092118 -
The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
|
Phase 3 | |
| Completed |
NCT00839189 -
Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults
|
Phase 1 | |
| Completed |
NCT00570492 -
Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.
|
Phase 4 | |
| Completed |
NCT00806754 -
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)
|
Phase 4 | |
| Recruiting |
NCT00153595 -
EWO1 in Persistent Allergic Rhinitis Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT00132925 -
An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT02498509 -
Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
|
Phase 3 | |
| Completed |
NCT01134705 -
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
|
Phase 3 |